Orient Pharma Co., Ltd. (4166) AI Stock Analysis

Orient Pharma Co., Ltd.

(TPEx:4166)

Select Model

Rating:75Outperform

Price Target:TWD 25.00▲(10.86% Upside)

Action:initiatedcoverage

Date:11/10/26

Strong financial performance is the primary support for the score, driven by improved profitability, low leverage, and stronger cash generation. This is moderated by weak technical momentum and a moderate P/E valuation, while earnings-call and corporate-event factors were excluded.

Positive Factors

Profitability turnaroundThe shift from losses to sustained profitability across 2023–2025 indicates a meaningful improvement in operating performance. Healthy 2025 gross and net margins provide an earnings base that can support reinvestment, strengthen resilience, and improve the company’s ability to fund growth.

Negative Factors

Volatile historical cash flowThe history of negative cash flow shows that recent improvement has not yet eliminated variability in cash generation. If operating performance weakens, uneven conversion from earnings to cash could constrain investment capacity and make internally funded growth less dependable.

Orient Pharma Co., Ltd. (4166) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 5.41B
Dividend Yield: ―
Average Volume (3M): 88.52K
Price to Earnings (P/E): 22.8
Beta (1Y): 0.33
Revenue Growth: ―
EPS Growth: ―
Country: TW
Employees: 173
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Orient Pharma Co., Ltd. Business Overview & Revenue Model

Company Description

Orient Pharma Co., Ltd., established in Taipei, Taiwan, in 2008, is a global pharmaceutical company engaged in the research, development, production, and sales of medicinal products. Its extensive pipeline addresses diverse therapeutic areas, includi...

Orient Pharma Co., Ltd. Financial Statement Overview

Summary

Strong recent financial recovery, supported by improved profitability, sharply lower debt, higher equity, and substantial operating and free cash flow growth. Historical cash-flow volatility, moderate ROE, and gross-margin compression limit the score.

Income Statement

86Very Positive

Balance Sheet

90Very Positive

Cash Flow

84Very Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.52B	1.40B	1.22B	889.91M	511.86M	463.34M
Gross Profit	831.77M	706.92M	651.56M	468.67M	155.35M	142.67M
EBITDA	387.56M	396.67M	312.81M	172.40M	35.37M	-39.21M
Net Income	235.25M	208.44M	107.37M	22.29M	-28.76M	-102.65M
Balance Sheet
Total Assets	3.01B	2.94B	2.52B	2.56B	1.85B	1.76B
Cash, Cash Equivalents and Short-Term Investments	585.05M	627.40M	109.30M	113.12M	97.23M	151.72M
Total Debt	189.61M	195.97M	546.78M	716.93M	508.21M	415.33M
Total Liabilities	353.90M	374.88M	733.00M	892.18M	757.65M	647.90M
Stockholders Equity	2.66B	2.56B	1.79B	1.67B	1.09B	1.12B
Cash Flow
Free Cash Flow	201.55M	324.32M	169.60M	-176.51M	-17.54M	-123.56M
Operating Cash Flow	291.69M	360.13M	197.01M	-102.99M	11.38M	-53.56M
Investing Cash Flow	-209.76M	-73.07M	-22.48M	-88.02M	-29.09M	55.81M
Financing Cash Flow	285.18M	217.75M	-173.36M	197.90M	-36.79M	79.11M

Orient Pharma Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4166 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4166	75Outperform	TWD 5.47B	22.78	―	―	―	―
TW:1734	64Neutral	TWD 6.07B	17.33	―	3.13%	2.44%	-3.96%
TW:4746	64Neutral	TWD 5.43B	11.42	―	6.61%	-2.71%	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4157	52Neutral	TWD 5.78B	37.38	―	―	530.40%	―
TW:4119	48Neutral	TWD 5.85B	95.69	―	1.55%	-18.83%	-87.54%
TW:6785	41Neutral	TWD 5.11B	-73.49	―	0.12%	-57.57%	-312.45%

* General Sector Average

Performance Comparison

TW:4166 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4166	Orient Pharma Co., Ltd.	22.55	-1.95	-7.96%
TW:1734	Sinphar Pharmaceutical Co. Ltd.	30.15	1.89	6.71%
TW:4119	SCI Pharmtech Corp.	48.50	-0.42	-0.85%
TW:4157	TaiGen Biopharmaceuticals Holdings Limited	8.29	-1.17	-12.37%
TW:4746	Formosa Laboratories, Inc.	45.40	-15.89	-25.92%
TW:6785	Alar Pharmaceuticals Inc	80.10	-172.14	-68.25%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Orient Pharma Co., Ltd. AI Stock Analysis